News Release Details
Verrica Pharmaceuticals Announces Appointment of Terry Kohler as Chief Financial Officer
Company strengthens management team in anticipation of the potential commercial launch of VP-102, if approved
“Terry’s extensive commercial finance experience across the pharmaceutical product development landscape, including buy and bill business model, as well as his commercial acumen across all classes of trade, will support our commercial preparations for the potential launch of VP-102 this fall,” said
“I am thrilled to join Verrica and oversee commercial financial strategy to advance Verrica’s medical dermatology product portfolio,” said
Prior to joining Verrica,
About
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s late-stage product candidate, VP-102, is in development to treat molluscum, common warts and external genital warts, three of the largest unmet needs in medical dermatology. Verrica is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. The Company has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology conditions. For more information, visit www.verrica.com.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Verrica’s current beliefs and expectations. These forward-looking statements include expectations regarding the potential approval and commercial launch of VP-102 for the treatment of molluscum and the clinical development of VP-102 for additional indications. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the drug development process and the regulatory approval process, Verrica’s reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in Verrica’s Annual Report on Form 10-K for the year ended
FOR MORE INFORMATION, PLEASE CONTACT:
Investors:
Solebury Trout
646.378.2946
wwindham@soleburytrout.com
Media:
Solebury Trout
646.378.2960
zlockshin@soleburytrout.com
Source: Verrica Pharmaceuticals Inc.